In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 3, 2000, Pages 213-219

  Hostetler, Karl Y ^a   Hammond, Jennifer L ^b   Kini, Ganesh D ^d   Hostetler, Saskia E ^a   Beadle, James R ^a   Aldern, Kathy A ^a   Chou, Ting Chao ^c   Richman, Douglas D ^a   Mellors, John W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NONE

Author keywords

AIDS; Combination index; Ether lipids; Foscarnet; Human immunodeficiency virus type 1; Phosphonoformate; Prodrugs; Synergy; Zidovudine

Indexed keywords

ALKYL GROUP; CARBON; CD4 ANTIGEN; FOSCARNET DERIVATIVE; GLYCEROL; OCTADECYL SN GLYCERO 3 PHOSPHONOFORMATE ANALOGUE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0033946525     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100304     Document Type: Article

References (22)

1. Beadle JR, Kini GD, Aldern KA, Gardner MF, Wright KN, Richman DD & Hostetler KY (1998) Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1 infected cells. Antiviral Research 9:33-40.
2. Cesarotti E, Antognazza P, Pallavicini M & Villa L (1993) Synthesis and rethenium-catalyzed enantioselective hydrogenation of 3-O-substituted 1,3-dihydroxypropan-2-ones. Helvetica Chimica Acta 76:2344-2349.
3. 50, synergism and antagonism. Cambridge, UK; Elsevier-Biosoft.
4. Chou T-C & Talalay P (1984) Quantitative analysis of dose-effect relationship: the combined effects of multiple drug or enzyme inhibitors. Advances in Enzyme Regulation 22:27-55.
5. Chrisp P & Clissold SP (1991) Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
6. Eriksson BFH & Schinazi RF (1989) Combinations of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 33:663-669.
7. Farthing CF, Dalgleish AG, Clark A, McClure M, Chanas A & Gazzard BG (1987) Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. AIDS 1:21-25.
8. Fletcher CV, Collier AC, Rhame FS, Bennet D, Para MF, Beatty CC, Jones CE & Balfour HH (1994) Foscarnet for the suppression of human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy 38:604-607.
9. Hostetler KY, Kini GD, Beadle JR, Aldern KA, Gardner MF, Border R, Barshak L, Kumar R, Sridhar CN, Wheeler CJ & Richman DD (1996) Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Antiviral Research 31:59-67.
10. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N & Mills J (1988) Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. Journal of Infectious Diseases 158:862-865.
11. Kini GD, Beadle JR, Xie H, Aldern KA, Richman DD & Hostetler KY (1997a) Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. Antiviral Research 36:43-53.
12. Kini GD, Hostetler SE, Beadle JR & Aldern KA (1997b) Synthesis and antiviral activity of 1-O-octadecyl-2-O-alkyl-sn-glycero-3-foscarnet conjugates in human cytomegalovirus-infected cells. Antiviral Research 36:115-124.
13. Krugner-Higby L, Goff D, Edwards T, Iyer N, Neufeld J, Kute T, Morris-Natschke S, Ishaq K, Piantadosi C & Kucera LS (1995) Membrane-interactive phospholipids inhibit HIV type-1 induced cell fusion and surface gp160/gp120 binding to monoclonal anti-body. AIDS Research and Human Retroviruses 11:705-712.
14. Kucera LS, Iyer N, Leake E, Raben A, Modest EJ, Daniel LW & Piantadosi C (1990) Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Research and Human Retroviruses 6:491-501.
15. Larder BA, Darby G & Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
16. Mellors JW, Bazmi H, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J & Mayers DL (1995) Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrobial Agents and Chemotherapy 39:1087-1092.
17. Meyer PR, Matsuura SE, So AG & Scott WA (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proceedings of the National Academy of Sciences, USA 95:13471-13476.
18. Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB & Jacobson MA (1992) Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. Journal of Infectious Diseases 166:607-610.
19. Tachedjian G, Hooker DJ, Gurusinghe AD, Bazmi H, Deacon NJ, Mellors JW, Birch C & Mills J (1995) Characterization of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212:58-68.
20. Tachedjian G, Mellors JW, Bazmi H, Birch C & Mills J (1996) Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. Journal of Virology 70:7171-7181.
21. Tachedjian G, Mellors JW, Bazmi H & Mills J (1998) Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 14:1059-1064.
22. Tachedjian G, French M & Mills J (1998) Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobal Agents and Chemotherapy 42:3038-3043.